677 related articles for article (PubMed ID: 7884953)
21. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study.
Huang W; Qiu C; von Strauss E; Winblad B; Fratiglioni L
Arch Neurol; 2004 Dec; 61(12):1930-4. PubMed ID: 15596614
[TBL] [Abstract][Full Text] [Related]
22. [Patterns of cognitive impairment and apolipoprotein genotype in persons with Alzheimer's disease].
Łuczywek E; Pffefer A; Nowicka A; Czyzewski K; ŁaŁowski M; Styczyńska M; Barcikowska M
Neurol Neurochir Pol; 2001; 35(6):1021-33. PubMed ID: 11987699
[TBL] [Abstract][Full Text] [Related]
23. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease.
Martinez M; Campion D; Brice A; Hannequin D; Dubois B; Didierjean O; Michon A; Thomas-Anterion C; Puel M; Frebourg T; Agid Y; Clerget-Darpoux F
Arch Neurol; 1998 Jun; 55(6):810-6. PubMed ID: 9626772
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease.
Hashimoto M; Yasuda M; Tanimukai S; Matsui M; Hirono N; Kazui H; Mori E
Neurology; 2001 Oct; 57(8):1461-6. PubMed ID: 11673590
[TBL] [Abstract][Full Text] [Related]
26. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects.
Engelborghs S; Dermaut B; Goeman J; Saerens J; Mariën P; Pickut BA; Van den Broeck M; Serneels S; Cruts M; Van Broeckhoven C; De Deyn PP
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1148-51. PubMed ID: 12876259
[TBL] [Abstract][Full Text] [Related]
27. The effect of APOE epsilon4 allele on cerebral glucose metabolism in AD is a function of age at onset.
Hirono N; Hashimoto M; Yasuda M; Ishii K; Sakamoto S; Kazui H; Mori E
Neurology; 2002 Mar; 58(5):743-50. PubMed ID: 11889238
[TBL] [Abstract][Full Text] [Related]
28. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging.
Small GW; Komo S; La Rue A; Saxena S; Phelps ME; Mazziotta JC; Saunders AM; Haines JL; Pericak-Vance MA; Roses AD
Ann N Y Acad Sci; 1996 Dec; 802():70-8. PubMed ID: 8993486
[TBL] [Abstract][Full Text] [Related]
29. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.
Mosconi L; Perani D; Sorbi S; Herholz K; Nacmias B; Holthoff V; Salmon E; Baron JC; De Cristofaro MT; Padovani A; Borroni B; Franceschi M; Bracco L; Pupi A
Neurology; 2004 Dec; 63(12):2332-40. PubMed ID: 15623696
[TBL] [Abstract][Full Text] [Related]
30. Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
Lasser RA; Dukoff R; Levy J; Levin R; Lehtimäki T; Seubert P; Sunderland T
Int J Geriatr Psychiatry; 1998 Nov; 13(11):767-74. PubMed ID: 9850873
[TBL] [Abstract][Full Text] [Related]
31. Patterns of brain activation in people at risk for Alzheimer's disease.
Bookheimer SY; Strojwas MH; Cohen MS; Saunders AM; Pericak-Vance MA; Mazziotta JC; Small GW
N Engl J Med; 2000 Aug; 343(7):450-6. PubMed ID: 10944562
[TBL] [Abstract][Full Text] [Related]
32. [Apolipoprotein E gene polymorphisms and Alzheimer disease].
Chen D; Zhang JW; Zhang ZX; Zhao HL; Li XQ; Wu YN; Qu QM
Yi Chuan Xue Bao; 2003 Dec; 30(12):1167-70. PubMed ID: 14986436
[TBL] [Abstract][Full Text] [Related]
33. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.
Reiman EM; Chen K; Alexander GE; Caselli RJ; Bandy D; Osborne D; Saunders AM; Hardy J
Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8299-302. PubMed ID: 15932949
[TBL] [Abstract][Full Text] [Related]
34. [Apolipoprotein E 4 gene is a risk factor for Alzheimer's disease].
Peng D; Xu X; Feng Y
Zhonghua Nei Ke Za Zhi; 2001 Oct; 40(10):688-90. PubMed ID: 11769724
[TBL] [Abstract][Full Text] [Related]
35. No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease.
Murphy GM; Taylor J; Kraemer HC; Yesavage J; Tinklenberg JR
Am J Psychiatry; 1997 May; 154(5):603-8. PubMed ID: 9137113
[TBL] [Abstract][Full Text] [Related]
36. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.
Gomez-Isla T; West HL; Rebeck GW; Harr SD; Growdon JH; Locascio JJ; Perls TT; Lipsitz LA; Hyman BT
Ann Neurol; 1996 Jan; 39(1):62-70. PubMed ID: 8572669
[TBL] [Abstract][Full Text] [Related]
37. Glucose metabolism and gray-matter concentration in apolipoprotein E ε4 positive normal subjects.
Samuraki M; Matsunari I; Chen WP; Shima K; Yanase D; Takeda N; Matsuda H; Yamada M
Neurobiol Aging; 2012 Oct; 33(10):2321-3. PubMed ID: 22188720
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.
Premkumar DR; Cohen DL; Hedera P; Friedland RP; Kalaria RN
Am J Pathol; 1996 Jun; 148(6):2083-95. PubMed ID: 8669492
[TBL] [Abstract][Full Text] [Related]
39. Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study.
Mosconi L; Sorbi S; Nacmias B; De Cristofaro MT; Fayyaz M; Bracco L; Herholz K; Pupi A
Psychiatry Res; 2004 Feb; 130(2):141-51. PubMed ID: 15033184
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.
Corder EH; Saunders AM; Risch NJ; Strittmatter WJ; Schmechel DE; Gaskell PC; Rimmler JB; Locke PA; Conneally PM; Schmader KE
Nat Genet; 1994 Jun; 7(2):180-4. PubMed ID: 7920638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
